![David J. Valacer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
David J.
Valacer worked as the Chief Medical Officer at Molecular Templates, Inc. and as a Principal at Weill Cornell Medical College.
He also briefly returned to Molecular Templates, Inc. as Chief Medical Officer in 2017.
Valacer holds a graduate degree from New York University and a doctorate from the University of Vermont College of Medicine.
Antiguos cargos conocidos de David J. Valacer.
Empresas | Cargo | Fin |
---|---|---|
MOLECULAR TEMPLATES, INC. | Director Técnico/Científico/I+D | 20/10/2017 |
Weill Cornell Medical College | Corporate Officer/Principal | - |
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Director Técnico/Científico/I+D | - |
Formación de David J. Valacer.
New York University | Graduate Degree |
University of Vermont College of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
- Bolsa de valores
- Insiders
- David J. Valacer